Small-molecule targeting of MUSASHI RNA-binding activity in acute myeloid leukemia
小分子靶向MUSASHI RNA结合活性治疗急性髓系白血病
阅读:5
作者:Gerard Minuesa ,Steven K Albanese ,Wei Xie ,Yaniv Kazansky ,Daniel Worroll ,Arthur Chow ,Alexandra Schurer ,Sun-Mi Park ,Christina Z Rotsides ,James Taggart ,Andrea Rizzi ,Levi N Naden ,Timothy Chou ,Saroj Gourkanti ,Daniel Cappel ,Maria C Passarelli ,Lauren Fairchild ,Carolina Adura ,J Fraser Glickman ,Jessica Schulman ,Christopher Famulare ,Minal Patel ,Joseph K Eibl ,Gregory M Ross ,Shibani Bhattacharya ,Derek S Tan ,Christina S Leslie ,Thijs Beuming ,Dinshaw J Patel ,Yehuda Goldgur ,John D Chodera ,Michael G Kharas
| 期刊: | Nature Communications | 影响因子: | 14.700 |
| 时间: | 2019 | 起止号: | 2019 Jun 19;10(1):2691. |
| doi: | 10.1038/s41467-019-10523-3 | 方法学: | Cell sorting、FCM、WB |
| 研究方向: | 肿瘤 | 疾病类型: | 白血病 |
Abstract
The MUSASHI (MSI) family of RNA binding proteins (MSI1 and MSI2) contribute to a wide spectrum of cancers including acute myeloid leukemia. We find that the small molecule Ro 08-2750 (Ro) binds directly and selectively to MSI2 and competes for its RNA binding in biochemical assays. Ro treatment in mouse and human myeloid leukemia cells results in an increase in differentiation and apoptosis, inhibition of known MSI-targets, and a shared global gene expression signature similar to shRNA depletion of MSI2. Ro demonstrates in vivo inhibition of c-MYC and reduces disease burden in a murine AML leukemia model. Thus, we identify a small molecule that targets MSI's oncogenic activity. Our study provides a framework for targeting RNA binding proteins in cancer.
特别声明
1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。
2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。
3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。
4、投稿及合作请联系:info@biocloudy.com。